In a report released yesterday, Marc Frahm from TD Cowen maintained a Buy rating on Janux Therapeutics Inc (JANX – Research Report). The company’s shares closed yesterday at $6.56.
Frahm covers the Healthcare sector, focusing on stocks such as Incyte, Cardiff Oncology, and Puma Biotechnology. According to TipRanks, Frahm has an average return of 11.0% and a 43.55% success rate on recommended stocks.
Janux Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $35.00.
See today’s best-performing stocks on TipRanks >>
Based on Janux Therapeutics Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $1.06 million and a GAAP net loss of $17.51 million. In comparison, last year the company earned a revenue of $2.37 million and had a GAAP net loss of $16.89 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Janux Therapeutics Inc (JANX) Company Description:
Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer.
